Abstract
Introduction

55
In the event of tissue damage, whether caused by injury or infection, inflammation is 56 the body's first co-ordinated line of defence. It is responsible for activating both 57 innate and adaptive immune responses so that the damage can be resolved and 58 homeostasis restored. The characteristic signs of inflammation include heat, 59 redness, swelling and pain and are easily recognisable [1] . There are four stages to For example, products of the T H 2 immune response suppress the T H 1 immune 128 response and vice versa [17] . Without the ability to resolve the inflammation the 129 collateral damage to surrounding cells has the potential to be catastrophic resulting 130 in sepsis and even death. However, if it is controlled correctly, inflammation can be 131 resolved effectively with little or no long term damage to the host [18] . Similarly, the idea of using antibodies to directly and immediately boost the immune 232 system during infection has a long history of use, but is rarely used today. Sera from 
Targeting the Host
244
Both chronic infections and acute infections result in the induction of cytokine storms.
245
It is therefore becoming apparent that a combination therapy approach involving both 246 an anti-microbial compound along with an immunotherapy may produce a more 247 favourable outcome, and this is an area of intense investigation.
248
For an immunomodulatory therapeutic to be considered for treatment of infection, it 249 must not deleteriously affect "helpful" elements of the immune response. It also 250 needs to be specific for highly conserved networks that are essential to the host in 251 either maintaining immune homeostasis and/or in combating infection. In this review,
252
we focus on promising new therapeutic approaches in this area (Figure 2) , and discuss the advantages and disadvantages which will influence whether they gain 254 acceptance for the clinic.
255
Proinflammatory Cytokines
256
The therapeutic use of cytokines as non-specific immunomodulators that boost the Once an infection has progressed to a late stage and an individual begins to suffer 297 symptoms of disease (e.g. fever, pyrexia) the immune response generated at this 298 point can be detrimental to the host if cascades are not appropriately controlled. 
